Novartis shares rise 6% as remibrutinib meets MS Phase 3 goals

1. 1Novartis (NVS) shares rose 6% after the company said remibrutinib met its goals in a Phase 3 trial for multiple sclerosis.
2. 2The company said the drug reduced relapse rates and side effects at a higher rate than competing treatments.
3. 3The results are expected to boost pipeline confidence, with shares up 17% year to date.

Source Investopedia +2 · View original ↗

Today's 5 AI picks, all free

Nothing hidden: past picks and how they did against the S&P 500.

See today's picks →